Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline - Pharmaceutical Technology

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery. Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery. The biotech’s initial focus is on the treatment of severe neurogenic bladder conditions. Credit: Oleksandr Drypsiak/Shutterstock.com. Paris-based biotech Cyllene Therapeutics has raised €33m ($37.75m) to advance its pipeline of gene therapies headed by lead candidate EG110A for the treatment of severe neurogenic bladder conditions. The Series C was co-led by Merck KGaA’s…

Source: Pharmaceutical Technology